Role of cytokines in inducing hyperlipidemia.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic in vitro and animal studies
PubMed 1526345 · doi:10.2337/diab.41.2.s97
What was done
This narrative review synthesizes in vitro, animal, and clinical observations regarding how pro-inflammatory cytokines affect lipid metabolism. It examines the mechanisms by which molecules such as tumor necrosis factor (TNF), interleukin-1 (IL-1), interleukin-6 (IL-6), and interferons alter hepatic lipid secretion, peripheral lipolysis, and lipoprotein interactions during conditions like diabetes.
What was found
The abstract reports no numerical data or effect sizes. Mechanistically, it reports that TNF rapidly increases serum triglyceride and normal-composition VLDL levels by stimulating hepatic de novo fatty acid synthesis and peripheral lipolysis rather than impairing clearance. Hepatic fatty acid synthesis is also stimulated by IL-1, IL-6, and alpha-interferon, while lipolysis is stimulated by IL-1 and alpha-, beta-, and gamma-interferon. Additionally, the review notes that lipoproteins bind endotoxins, viruses, and urate crystals, potentially reducing their toxicity or infectivity.
Why it matters
The paper outlines how cytokine-driven hyperlipidemia in inflammatory and diabetic states may function as a regulated host-defense mechanism to neutralize toxins and pathogens rather than serving solely as a metabolic defect.
Limits
This is a narrative review without systematic search criteria, defined human sample sizes, or quantitative outcome data. Many mechanistic assertions rely on in vitro and animal models that may not translate directly to human pathophysiology.
Cited by
- supports Pro-inflammatory cytokines including TNF-alpha and interferon stimulate VLDL secretion by the liver within minutes.